Press release
New Investigational Drug TB006 FDA - Approved For Compassionate Use
Naples, FL - April 21, 2025 - TB006, a new investigational drug, has been approved by the US Food and Drug Administration (FDA) for compassionate use and is currently being evaluated in a clinical trial for Alzheimer's disease. The FDA's compassionate use designation allows patients with serious or life-threatening conditions to access investigational treatments when no satisfactory alternatives are available.TB006 is currently undergoing clinical trials to assess its safety and potential effects on inflammation and cognitive function in individuals diagnosed with Alzheimer's disease. According to clinical investigators involved in early-stage research, the drug has been administered to over 300 patients to date, with no adverse side effects reported.
Preliminary data from a placebo-controlled trial [https://alzheimersnewstoday.com/news/signs-alzheimers-reversed-eased-after-3-months-tb006/] suggested that:
*
Nearly half of those who took TB006 for at least 3 months showed signs of disease reversal and cognitive improvement
*
Those who took TB006 had lower levels of inflammation. Reducing inflammation is very important because inflammation is a major cause of Alzheimer's disease.
These findings are currently being further investigated through ongoing clinical studies. With Alzheimer's disease on the rise, this is very exciting news for those over age 65 and those with a history of dementia in their family.
Among the clinical sites authorized to provide TB006 under compassionate use is Brain Power Clinics, located in West Palm Beach, Florida. The clinic is led by Dr. Joshua Helman, a Harvard-trained physician with over a decade of experience focused on integrative approaches to cognitive decline. Known to patients as Dr. Josh, he currently administers TB006 under FDA protocols as part of a broader, individualized care model.
Dr. Helman works in partnership with Dr. Robert Love, Ph.D., a neuroscientist recognized for his contributions to the field of Alzheimer's prevention and brain health. Together, the team at Brain Power Clinics offers a multidisciplinary approach that combines investigational therapies like TB006 with behavioral coaching and lifestyle interventions designed to support cognitive function.
Participation in the compassionate use program is limited to individuals who meet specific eligibility criteria, which include age and diagnosis parameters in accordance with FDA and clinical trial guidelines.
To learn more about working with Dr. Josh in his medical clinic, please text "Memory" to 561-725-3319 or visit www.BrainPowerClinics.com [http://www.brainpowerclinics.com/].
Disclaimer: The expert opinions presented in this PR/Story are based on the extensive experience and knowledge of the source company. These views do not necessarily reflect the opinions of the news distribution company and its distribution partners. There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any medical treatment, product, or service in this article. Moreover, nothing contained in this should be construed as medical advice or a recommendation to start, stop, or change any medical treatment or medication. It is your responsibility to determine whether any medical treatment, product, or service is appropriate for you based on your health objectives, medical condition, and risk tolerance. Consult your healthcare provider regarding your specific medical situation. The news distribution company and its distribution partners do not endorse or guarantee the accuracy, completeness, or reliability of the information shared by the guest. Viewers are encouraged to consult with their own healthcare professionals or conduct their own research when making decisions related to medical topics. The source company is the one issuing this release. Please contact them directly for further information.
Media Contact
Company Name: Brain Power Clinics
Contact Person: Robert Love
Email: Send Email [http://www.universalpressrelease.com/?pr=new-investigational-drug-tb006-fda-approved-for-compassionate-use]
Phone: 305-209-0853
Country: United States
Website: http://www.BrainPowerClinics.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New Investigational Drug TB006 FDA - Approved For Compassionate Use here
News-ID: 3980033 • Views: …
More Releases from Getnews

Niqo Robotics Launches AI-Powered Precision Weeding Robot at FIRA USA 2025
Niqo Robotics Enters Weeding Segment With AI Spot-Spray Robots Delivering Precision Weeding at 4.5 miles per hour [https://drive.google.com/drive/folders/1voHyUysI-BvQkzn_no_RwiRh2bK0EvMn]
- Niqo's weeding robot debuts at FIRA USA 2025
- Industry-best precision weeding speed of 4.5 mph
- Optimized for specialty crops segment
- Delivers full ROI in under two seasons
Niqo Robotics, a leading provider of AI-powered robotics for sustainable farming, today announced its entry into the weeding segment with the launch of its precision weeding…

McDonald's NY Tri-State Owner/Operators Celebrate Hispanic Heritage Month
Image: https://www.globalnewslines.com/uploads/2025/10/1761072908.jpg
McDonald's NY Tri-State Owner/Operators Hispanic Heritage Month 2025
Honoring Culture, Legacy & Leadership - Powered by 360WiSE Registered Media
Miami, FL - October 21, 2025 - The McDonald's NY Tri-State Owner/Operators Association proudly celebrated Hispanic Heritage Month 2025, honoring the culture, legacy, and leadership of Hispanic trailblazers whose influence continues to shape America's story. Presented in collaboration with 360WiSE Registered Media, the campaign featured educational content highlighting icons such as Luis…

Captain Eddie Gantner Soars Again with His Remarkable Memoir, Vagabond Chronicle …
Image: https://www.globalnewslines.com/uploads/2025/10/1761071726.jpg
An unforgettable journey through the golden age of aviation, told by a man who lived it.
Veteran aviator Captain Eddie Gantner invites readers into the cockpit of history with his gripping new memoir, Vagabond Chronicles: Legacy of the Blue. Spanning decades of flight, danger, and discovery, the book offers a rare, first-hand look into the heart of aviation, from war zones and stormy skies to quiet moments of reflection above…

BenaVest Partners with BackNine to Offer Life and Annuity Solutions Through Quot …
Hollywood, FL - BenaVest, a leading national insurance FMO General Agency specializing in ACA, Medicare, Life, and Annuity products, is excited to announce a new partnership with BackNine Insurance & Financial Services. This collaboration gives BenaVest agents direct access to BackNine's Quote & Apply Trademark life insurance platform, an innovative digital tool that simplifies the quoting and application process for both agents and clients.
With Quote & Apply Trademark , agents…
More Releases for TB006
Alzheimer's Disease Competitive Landscape 2025: Clinical Trial Analysis, Therapi …
(Albany, USA) DelveInsight's latest report, "Alzheimer's Disease Pipeline Insight 2025", provides an in-depth and data-driven analysis of the global Alzheimer's disease (AD) clinical trial landscape, highlighting key EMA, FDA, and PDMA regulatory updates, emerging therapies, and market trends shaping the future of Alzheimer's treatment.
With 110+ active players and over 120 pipeline drugs under development, the Alzheimer's therapeutic domain continues to evolve with rapid advancements in disease-modifying treatments, biomarkers, and neuroprotective…
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA Approvals, Treatment Ma …
(Albany, USA) DelveInsight's 'Alzheimer's disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Alzheimer's disease therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Alzheimer's disease pipeline domain.
For Alzheimer's disease emerging drugs, the Alzheimer's disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration,…
FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southe …
West Palm Beach, FL - May 5, 2025 - Brain Power Clinics, a Florida-based healthcare provider specializing in cognitive conditions, announces the availability of TB006 for compassionate use in the treatment of Alzheimer's disease. The new drug, currently in clinical trials, has shown promising early results in addressing memory loss and other symptoms associated with dementia.
Promising New Treatment for Alzheimer's Disease
TB006, now available through Brain Power Clinics in Southern Florida,…
Alzheimer's Disease Drug Development Pipeline: 2025-A Surge in Innovation as 110 …
DelveInsight unveils its latest report, highlighting the evolving landscape of the Alzheimer's disease pipeline, with over 110 pharma and biotech companies like BioVie, Novo Nordisk, Alector, Longeveron, Cognition Therapeutics, TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme LLC, and Regeneration Biomedical, advancing novel Alzheimer's disease drugs set to reshape the Alzheimer's disease market.
The fight against Alzheimer's disease is gaining momentum. In its newly released "Alzheimer's disease…
Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Land …
The Dementia Market size was valued approximately USD 21 million in 2021 and the report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the 7MM.
DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy,…
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Ischemic Stroke Pipeline Report
• Over 50+ Ischemic Stroke…